Aspirin 75

Phase 3Small molecule

Aspirin 75 is one of 97 small molecule programs targeting Sudden Sensorineural Hearing Loss. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sudden Sensorineural Hearing LossActive, not recruiting

StrokeActive, not recruiting

AtherosclerosisActive, not recruiting

Cerebral InfarctionActive, not recruiting

Sudden Sensorineural Hearing LossPhase 3

Active, not recruiting

StrokePhase 3

Active, not recruiting

AtherosclerosisPhase 3

Active, not recruiting

Cerebral InfarctionPhase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Aspirin 75

Merck & Co.

Phase 3

1 2

Activase

Roche

Preclinical

19 3

Zometa

Pfizer

Preclinical

1 4

Folvite

Eli Lilly

Preclinical

1 5

Proamatine

Takeda

Preclinical

—6

Botox

RRevance Therapeutics, Inc.

Preclinical

2 7

Zantac 150

CChattem

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Direct Anticoagulant

Bayer

Preclinical

3 10

Anticoagulants

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Atherosclerosis

NCT05476991

Q1 2029

Phase 3Not yet recruiting

Oral Anticoagulation

NCT05687448

Q4 2029

Phase 3Not yet recruiting

Sudden Sensorineural Hearing Loss

NCT07113158

Clinical

Trials by Indication[1]

Atherosclerosis1 trial

Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05476991·2,800 enrolled

Perioperative Period1 trial

STRATAGEM: Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00190307·293 enrolled

Antiplatelet Therapy1 trial

Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00827411·2,500 enrolled

Stroke1 trial

Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke

Completed· Otsuka logo

Otsuka·Phase 3·NCT00202020·720 enrolled

Oral Anticoagulation1 trial

DIrect Oral Anticoagulation and Bioprothesis Aortic Valve

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05687448·1,500 enrolled

2 more indications

Sudden Sensorineural Hearing Loss1 trial

Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07113158·142 enrolled

Cerebral Infarction1 trial

Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00684515·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Aspirin 75. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aspirin 75 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aspirin 75. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Aspirin 75

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2029

Q4 2029

Trials by Indication[1]

Atherosclerosis1 trial

Perioperative Period1 trial

Antiplatelet Therapy1 trial

Stroke1 trial

Oral Anticoagulation1 trial

Sudden Sensorineural Hearing Loss1 trial

Cerebral Infarction1 trial

References

Drug Info

Quick Facts

Related News